John Greene
CIK: 0001610732
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 5, 2026CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
13K shares- - Feb 11, 2026NOC
NORTHROP GRUMMAN CORP /DE/
Award(A)DirectRestricted Stock Rights
5.4K shares- - Feb 11, 2026NOC
NORTHROP GRUMMAN CORP /DE/
Award(A)DirectRestricted Performance Stock Rights
5K shares- - Jun 5, 2025CRSP
CRISPR Therapeutics AG
Award(A)DirectStock Option (Right to Buy)
13K shares- - May 18, 2025DFS
Discover Financial Services
Disposition(D)Direct79.9K shares- - Feb 26, 2025CRSP
CRISPR Therapeutics AG
Purchase(P)Direct7K shares at avg. $44.85$314K - Feb 1, 2025DFS
Discover Financial Services
Tax Payment(F)Direct1.8K shares at avg. $201.09$370K - Jan 23, 2025DFS
Discover Financial Services
Award(A)Direct14.6K shares- - Dec 19, 2024DFS
Discover Financial Services
Tax Payment(F)Direct11.7K shares at avg. $169.27$2.0M - Dec 19, 2024DFS
Discover Financial Services
Award(A)Direct12.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 13,000 | - | - | Direct |
| Feb 11, 2026 |  NOC NORTHROP GRUMMAN CORP /DE/ | Award(A) Restricted Stock Rights | 5,362 | - | - | Direct |
| Feb 11, 2026 | NOC NORTHROP GRUMMAN CORP /DE/ | Award(A) Restricted Performance Stock Rights | 4,981 | - | - | Direct |
| Jun 5, 2025 | CRSP CRISPR Therapeutics AG | Award(A) Stock Option (Right to Buy) | 13,000 | - | - | Direct |
| May 18, 2025 |  DFS Discover Financial Services | Disposition(D) | 79,943 | - | - | Direct |
| Feb 26, 2025 | CRSP CRISPR Therapeutics AG | Purchase(P) | 7,000 | $44.85 | $313,948 | Direct |
| Feb 1, 2025 | DFS Discover Financial Services | Tax Payment(F) | 1,840 | $201.09 | $370,006 | Direct |
| Jan 23, 2025 | DFS Discover Financial Services | Award(A) | 14,630 | - | $0 | Direct |
| Dec 19, 2024 | DFS Discover Financial Services | Tax Payment(F) | 11,702 | $169.27 | $1,980,798 | Direct |
| Dec 19, 2024 | DFS Discover Financial Services | Award(A) | 12,109 | - | $0 | Direct |
1-10 of 10 transactions
About Greene John
Greene John (SEC CIK 0001610732) files insider reports with the SEC as Director of CRISPR Therapeutics AG (CRSP), CVP & Chief Financial Officer of NORTHROP GRUMMAN CORP /DE/ (NOC) and EVP, Chief Financial Officer of Discover Financial Services (DFS).
Signal8 holds 9 ownership filings by Greene John (1 Form 3, 8 Form 4), filed between Dec 23, 2024 and Jun 9, 2026. Those filings report 10 transactions, from Dec 19, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Greene John's filings is in BOSTON, MA.
Recent filings by Greene John
- Jun 5, 2026: Grant or award of CRSP derivative securities (Form 4, code A).
- Feb 11, 2026: Grants or awards of NOC derivative securities (2 lines, Form 4, code A).
- Jun 5, 2025: Grant or award of CRSP derivative securities (Form 4, code A).
- May 18, 2025: Disposition to issuer transaction of DFS shares (Form 4, code D).
- Feb 26, 2025: Open-market purchase of CRSP shares (Form 4, code P).
Other insiders filing for CRISPR Therapeutics AG (CRSP)
- Sakhamuri Sivakesava, Chief Technical Officer
- Silver Andrew Jacob, Chief Financial Officer
- KASINGER JAMES R., General Counsel and Secretary
- Kulkarni Samarth, Chief Executive Officer
- Patel Naimish, Chief Medical Officer
- George Simeon, Director